Loading JYL Briefings...

AI & Tech Life Sciences About Jae Subscribe

Life Sciences / Regulatory

Life Sciences / Regulatory briefings.

Weekly briefs and quarterly reviews on FDA policy, clinical AI evidence, biotech platform shifts, trial infrastructure, and the regulatory pathways that decide whether products can actually ship.

OCT 2026W41Oct 5 - Oct 11The UK and California wrote clinician oversight, developer bias duties and lifecycle change control into health-AI policy, 3 preprints measured how those checks perform, and MHRA showed a point-of-care QC failure turn...Weekly Brief · 22 min read SEP 2026W40Sep 28 - Oct 4A light week, with two FDA actions and a short stack of journal and preprint work, and all four items that matter put the evidence burden after the headline decision: in follow-up studies, in EMR plumbing, in the huma...Weekly Brief · 14 min read W39Sep 21 - Sep 27A quieter week with four real moves, and all four relocate the evidence question: from the AI component to the composed system, from test accuracy to label scope, from rule text to method validation, and from regulato...Weekly Brief · 16 min read W38Sep 14 - Sep 20This week the clinical-AI conversation moved from "what does the model score" to "who verified it, against what reference, under what monitoring," and the same question showed up in a journal framework, a preprint ben...Weekly Brief · 19 min read W37Sep 7 - Sep 13This week clinical AI stopped being a model-performance story and became a lifecycle-governance story, with funders, regulators, journals, and quality teams all designing for what happens after a model is deployed.Weekly Brief · 13 min read AUG 2026W36Aug 31 - Sep 6A week about who gets to decide what counts as evidence, and where that decision now sits. The UK moved the device question upstream into primary legislation and downstream into an NHS ward. FDA moved the oncology evi...Weekly Brief · 30 min read W35Aug 24 - Aug 30A decision week, not a discussion week. Last week FDA opened a question set on generative-AI devices. This week it granted a new device type, opened a comment docket, and scheduled a validation workshop, three differe...Weekly Brief · 30 min read W34Aug 17 - Aug 23After two quiet weeks, CDRH did all the talking, and it talked in three registers at once: a discussion paper that opens the generative-AI device framework, a De Novo that authorizes a robot to put a needle in an arm,...Weekly Brief · 24 min read W33Aug 10 - Aug 16Three things landed in a quiet week, and each one is about control surfaces rather than approvals: a threshold you can turn, a data-handling obligation you have to scope, and a lot number you have to find in your inve...Weekly Brief · 22 min read W32Aug 3 - Aug 9A narrow week, and the narrowness is the signal: almost nothing shipped, and what did ship was all about how a claim gets proven rather than what got approved. FDA put the highest-profile multi-cancer screening test i...Weekly Brief · 22 min read JUL 2026W31Jul 27 - Aug 2Two regulators worked the same question this week — how much structure to put around AI that touches a patient — and answered it in opposite registers. MHRA built routes in: a live-deployment sandbox with an open appl...Weekly Brief · 28 min read W30Jul 20 - Jul 26A quiet week for pathway news, and the sharpest document of it came from outside the regulatory system: an independent evaluation putting a launched consumer AI health-triage product at roughly coin-flip agreement wit...Weekly Brief · 25 min read W29Jul 13 - Jul 19The week's throughline was where the regulated boundary sits for AI in care — and four parties spent it arguing from four directions: a regulator drafting the on-ramp, a legislature wiring AI into payment denial, clou...Weekly Brief · 13 min read W28Jul 6 - Jul 12The week's throughline was regulators writing the rulebook for AI-enabled devices ahead of the products — a cross-jurisdiction lifecycle framework closing consultation, a dated EU disclosure obligation that secondary...Weekly Brief · 13 min read JUN 2026W27Jun 29 - Jul 5The week's throughline was the gap between capability and clearance: a research tool that ships with auditable artifacts but no regulatory framing, a device that becomes the first patient-facing LLM to clear FDA, a jo...Weekly Brief · 14 min read W26Jun 22 - Jun 28The evidence bar for clinical AI rose this week — not from a regulator, but from the journals regulators and procurement committees cite, while capital and Congress redrew the map underneath it.Weekly Brief · 15 min read W25Jun 15 - Jun 21The week's signal: capability is racing ahead of clearance — from a consumer imaging device launched outside the 510(k) gate to general-purpose LLMs beating purpose-built clinical tools, while the FDA itself loosens t...Weekly Brief · 13 min read W24Jun 8 - Jun 14The week's signal: the general-purpose model beat the purpose-built clinical tool on every axis, capital and validation arguments split in opposite directions, and review-process integrity became the variable founders...Weekly Brief · 14 min read W23Jun 1 - Jun 7The week's signal clustered on one move: regulators and builders both started treating AI as qualified evidence infrastructure — a toxicology predictor entering FDA's tool pipeline, an audited LLM clearing a national...Weekly Brief · 16 min read MAY 2026W22May 25 - May 31The week's signal: computational evidence moved from supplement to pathway-grade. A protein-biology world model shipped under MIT license with lab-confirmed binders, FDA put organoids, microphysiological systems, and...Weekly Brief · 17 min read W21May 18 - May 24Computational drug design crossed a generalization threshold, agentic AI absorbed thirty life-science databases into one query surface, the UK proposed collapsing trial and marketing authorization into a single instru...Weekly Brief · 18 min read W20May 11 - May 17The inspection clock compressed, the UK device map redrew, a frontier multimodal diagnostic AI cleared peer review, the first BCL-2 inhibitor landed in mantle cell lymphoma on a triple-expedited stack, the 30-year FDA...Weekly Brief · 24 min read W19May 4 - May 10A new clinical modality cleared, the regulator's review stack went AI-augmented, the post-approval coverage gap collapsed, a top-5 pharma signed itself wall-to-wall to a frontier model vendor, and a state medical boar...Weekly Brief · 18 min read APR 2026W18Apr 27 - May 3The trial-data pipeline, the regulator's own org chart, and the implementation layer all moved this week — FDA collapsed batch-mode trial submission into continuous streaming with two named sponsors live, MHRA hired i...Weekly Brief · 16 min read W17Apr 20 - Apr 26The federal regulatory stack moved from talking about AI and access to enforcing them — pricing the cost of overreliance, compressing the timeline from authorization to coverage, and re-drawing the line between AI-ass...Weekly Brief · 22 min read W16Apr 13 - Apr 19The regulatory ceiling hardened on both sides of the Atlantic this week — and three frontier-AI vendors (Anthropic, OpenAI, AWS) each shipped their own biopharma-specific move in the same 48-hour window. The vendor-ev...Weekly Brief · 24 min read W15Apr 6 - Apr 12Five distinct regulatory and evidence surfaces shifted this week. Two are official pathway or regulatory actions (MHRA olezarsen approval and aligned pathway; FDA DHT RFI). Three are evidence-surface shifts (clinical-...Weekly Brief · 13 min read MAR 2026W14Mar 30 - Apr 5This week had one confirmed regulatory action (UK MHRA clinical trial timing reform), one strong peer-reviewed science cluster (drug delivery papers), and two preprint-stage signals (DFNZ opioid pharmacology and Speci...Weekly Brief · 12 min read W13Mar 23 - Mar 29Japan broke new ground by conditionally approving the world's first two iPSC-derived cell therapies, while the FDA approved the first gene therapy for LAD-I, the MHRA overhauled its approval timeline, and Lilly placed...Weekly Brief · 11 min read W12Mar 16 - Mar 22The FDA approved two first-in-class drugs in the same week — an oral IL-23 blocker for psoriasis and the first treatment for PBC-related itch — while two Nature papers converged on multi-organ axes for neurodegenerati...Weekly Brief · 8 min read W11Mar 9 - Mar 15The week's biggest signal is that AI-discovered drugs are generating real clinical data — and the regulatory system is simultaneously inventing new approval pathways to handle what comes next.Weekly Brief · 8 min read W10Mar 2 - Mar 8A Science paper reported a CD70-HIT CAR-T signal against "hidden" antigen expression that conventional assays miss, DeepMind's diagnostic AI posted 90% accuracy in a real primary care clinic, the FDA announced it will...Weekly Brief · 12 min read FEB 2026W09Feb 23 - Mar 1February's regulatory baseline still defined the March window: QMSR compliance had just gone mandatory, FDA had already cleared the first AI tool that simultaneously detects and characterizes lung cancer on CT, and gu...Weekly Brief · 12 min read W08Feb 16 - Feb 22The February 16-22 window captured the week the FDA's quality system changed and the major AI labs raced to add medical features without regulatory infrastructure — QMSR went live on February 2, the cybersecurity prem...Weekly Brief · 12 min read W07Feb 9 - Feb 15The February 9-15 window arrived one week after the most consequential device quality regulatory shift in three decades — QMSR's February 2 effective date — while the EMA-FDA joint AI principles published in January m...Weekly Brief · 12 min read W06Feb 2 - Feb 8The most significant regulatory infrastructure shift in 30 years hit enforcement this week: FDA's QMSR replaced the 1996 QSR on February 2, and FDA issued QMSR-aligned cybersecurity premarket guidance the very next da...Weekly Brief · 11 min read JAN 2026W05Jan 26 - Feb 1The late-January to early-February regulatory stack rewired itself across a window boundary: QMSR took effect Feb 2 replacing the inspection paradigm, the FDA deregulated swaths of CDS and wearable oversight, launched...Weekly Brief · 11 min read W04Jan 19 - Jan 25The FDA executed a coordinated January package across adjacent windows — W01 (Jan 6: CDS and General Wellness final guidances), W01 (Jan 14: FDA x EMA joint AI-in-drug-development principles), and now (W04: cleared de...Weekly Brief · 12 min read W03Jan 12 - Jan 18FDA deregulated two categories of AI health software simultaneously while opening a new limited review pathway for chronic disease digital health — the largest shift in the digital health regulatory posture in recent...Weekly Brief · 9 min read W02Jan 5 - Jan 11FDA opened 2026 with its largest digital health deregulation in a decade — revising CDS and general wellness guidance to remove premarket review from single-recommendation tools and non-invasive wearable monitoring —...Weekly Brief · 11 min read DEC 2026W01Dec 29 - Jan 4The opening January window of 2026 produced the most significant regulatory signal in recent memory: FDA and EMA issued their first joint AI principles for drug development, creating a transatlantic compliance baselin...Weekly Brief · 10 min read

Showing 41 weekly briefs